Brookfield Infrastructure Partners LP vs Revvity Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39.92 (market cap $18.10B), while Revvity Inc trades at $115.22 (market cap $12.91B). The key difference: Brookfield Infrastructure Partners LP is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| BIP | RVTY | |
|---|---|---|
Market Cap | $18.10B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $42.62 | $117.75 |
52-Week Low | $29.81 | $82.26 |
Enterprise Value | $77.05B | $15.23B |
Dividend Yield | 4.62% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.97, up 5.24% over 24 hours, with a bullish technical signal from moving averages. The stock shows strong analyst support with 13 buy ratings and a consensus price target of $44.67. Recent financials indicate revenue growth to $25.1 billion in 2026, though net income declined to $652 million. The company maintains a dividend yield with recent payouts of $0.46 per share and is undergoing corporate simplification to enhance shareholder value.
BIP presents a mixed outlook; attractive valuation metrics like EV/EBITDA of 6.97 and P/S of 0.72 suggest upside, but consecutive earnings misses and declining profitability margins pose risks. Investors may benefit from infrastructure demand and high dividend yields, yet should monitor execution on earnings targets and debt levels, with institutional sentiment leaning bullish amid macroeconomic uncertainties.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →